Arbutus Biopharma Corp
Uždarymo kaina
4.34 0.46
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
4.25
Max
4.38
Pajamos | 173M 170M |
|---|---|
Pardavimai | 178M 179M |
P/E Sektoriaus vid. | 5.398 49.888 |
Pelnas, tenkantis vienai akcijai | 1.19 |
Pelno marža | 94.735 |
Darbuotojai | 19 |
EBITDA | 177M 169M |
Kitas uždarbis | 2026-08-05 |
|---|
Rinkos kapitalizacija | 20M 885M |
|---|---|
Ankstesnė atidarymo kaina | 3.88 |
Ankstesnė uždarymo kaina | 4.34 |
Arbutus Biopharma Corp Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Arbutus Biopharma Corp Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
